Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy

Rebecca P. Sumner, Hongwei Ren and Geoffrey L. Smith

Vectors based on vaccinia virus (VACV), the vaccine used to eradicate smallpox, are currently popular candidates for the vaccination against numerous infectious diseases including malaria and AIDS. Although VACV induces robust cellular and humoral responses, enhancing the safety and efficacy of these vectors remains an important area of research. Here, we describe the enhanced immunogenicity of a recombinant VACV Western Reserve (WR) strain lacking the immunomodulatory protein C6 (vΔC6). Intradermal infection of mice with vΔC6 was shown previously to induce smaller lesions, indicating viral attenuation, and this was confirmed here using a different inoculation dose. In addition, data presented show that vaccination with vΔC6 provided better protection against challenge with a lethal dose of VACV WR, indicating this virus is a better vaccine. Increased protection was not due to improved humoral responses, but instead enhanced cytotoxic activity of T-cells 1 month post-inoculation in the spleens of vΔC6-vaccinated mice.

Vaccinia virus (VACV) is a member of the family Poxviridae, and is well known as the vaccine used for the eradication of smallpox (Fenner et al., 1988). VACV, like other poxviruses, is a large dsDNA virus that replicates in the cytoplasm of infected cells (Moss, 2007). Despite the eradication of smallpox, VACV is still studied intensively: as a tool for investigating host–pathogen interactions and as a vector for vaccine development. Recombinant VACVs were developed in the early 1980s (Mackett et al., 1982; Panicali & Paoletti, 1982) and are able to induce a strong host immune response, including both humoral (Panicali et al., 1983; Smith et al., 1983a, b) and cellular responses (Bennink et al., 1984) and activating both innate and adaptive components (Delaloye et al., 2009; Moss, 2011). The VACV strains used to eradicate smallpox caused some vaccine-related complications (Lane et al., 1969) and therefore more attenuated strains, such as the highly attenuated modified vaccinia virus Ankara (MVA), are being tested for vaccination against several infectious diseases including human immunodeficiency virus (HIV) and malaria (Gómez et al., 2008). Despite the loss of large sections of DNA following serial passage in chicken embryonic fibroblast cells (Meyer et al., 1991), the MVA genome still contains some immunomodulatory genes (Blanchard et al., 1998), the removal of which may enhance the immunogenicity of this vector.

VACV encodes around 200 genes, approximately half of which play essential roles in virus replication, morphogenesis and spread. The other half of the genome is made up of non-essential genes, many of which have been characterized to have roles in virus–host interactions including host tropism and evasion of immunity (Upton et al., 2003; Gubser et al., 2004; Lefkowitz et al., 2006). Removal of immune modulatory genes might lead to viral attenuation, and hence enhanced safety. Equally, the removal of genes that dampen the immune response may have a positive impact on immunogenicity. This has already been demonstrated with VACVs lacking several proteins that are secreted from the infected cell such as the chemokine-binding protein A41 (Clark et al., 2006), the IL-1β receptor B15 (Staib et al., 2005; Cottingham et al., 2008), the interferon (IFN) decoy receptors B18 and B8 (Gómez et al., 2012) and the IL-18-binding protein C12 (Reading et al., 2003b; Faliwere et al., 2012). Loss of intracellular proteins A35 (Rehm & Roper, 2011), the steroid biosynthetic enzyme 3-β-hydroxysteroid dehydrogenase (Moore & Smith, 1992; Reading et al., 2003a) and protein C6 (García-Arriaza et al., 2011) have all increased antigen-specific immune responses.

VACV WR protein C6 is a non-essential protein that is expressed early during infection (Assarsson et al., 2008; García-Arriaza et al., 2011; Unterholzner et al., 2011) and a predicted member of the VACV Bcl-2 family (Graham et al., 2008; Gonzalez & Esteban, 2010). Like other members of this family, C6 has an immunomodulatory function and inhibits the expression of IFN-β following stimulation of cells with multiple Toll-like receptor- and RIG-I-like-receptor-ligands by preventing the translocation of IFN regulatory factor (IRF)-3 into the nucleus (Unterholzner et al., 2011). Accordingly, C6 was found to interact with TRAF family member-associated NF-κB activator (TANK), NF-κB-activating kinase-associated protein 1 (NAP1) and similar
Engineered to lack C6 expression (vC6ΔC6), a matching wild-type virus expressing C6 (vC6Rev) (Unterholzner et al., 2011). A similar phenotype was also observed when mice were inoculated with 3 × 10⁶ p.f.u., with the lesion induced by vΔC6 being significantly smaller than that induced by the control viruses between 9 and 19 days post-infection (p.i.) (Fig. 1a). In contrast, when inoculated with 10⁴ p.f.u. the resulting lesions were similar in size (Fig. 1b), indicating that the observed attenuation of vΔC6 via this infection route is dose-dependent.

To test whether vΔC6 was more immunogenic than control viruses, mice immunized as above were challenged intranasally (i.n.) at 28 days p.i. (Williamson et al., 1990) with a lethal dose (at least 100 × LD₅₀) of wild-type WR (5 × 10⁶ p.f.u.). All three vaccination doses provided protection against this lethal challenge; however, at two of the doses tested (10⁴ p.f.u., Fig. 1c and 3 × 10⁵ p.f.u., Fig. 1d) the weight loss observed for the vΔC6-vaccinated animals was significantly less than control virus-vaccinated animals. The greatest difference in protection was observed following immunization with 10⁴ p.f.u. per ear, with vΔC6-vaccinated mice displaying a maximum mean weight loss of 6.4%, compared with 13.6% after immunization with control viruses (Fig. 1c).

To investigate the potential effect of the removal of C6 on VACV immunogenicity, groups of five C57BL/6 mice were immunized intradermally (i.d.) in both ear pinnae with either 10⁴ (c), 3 × 10³ (d) or 10³ (e) p.f.u. of the various C6 recombinant viruses at a dose of 3 × 10³ (a) or 10³ (b) p.f.u. in both ear pinnae were measured daily. Data are expressed as the mean lesion size (mm) ± SEM. Groups of five C57BL/6 mice that were vaccinated as described above with either 10⁴ (c), 3 × 10³ (d) or 10³ (e) p.f.u. were challenged i.n. (Williamson et al., 1990) 1 month later with a lethal dose of wild-type WR (5 × 10⁶ p.f.u.) and the resulting weight loss was monitored daily. Data are expressed as the percentage ± SEM of the mean weight of the same group of animals on day 0. Significant differences between groups are shown, as determined using the Student’s t-test (*P < 0.05). Data shown are representative of at least two experiments. All panels share the same figure legend, which is depicted in (b).

Fig. 1. Vaccination of mice with vΔC6 provides enhanced protection against challenge despite its lower virulence. The lesions induced by i.d. inoculation (Tscharke & Smith, 1999) of groups of five C57BL/6 mice with the various C6 recombinant viruses at a dose of 3 × 10³ (a) or 10³ (b) p.f.u. in both ear pinnae were measured daily. Data are expressed as the mean lesion size (mm) ± SEM. Groups of five C57BL/6 mice that were vaccinated as described above with either 10⁴ (c), 3 × 10³ (d) or 10³ (e) p.f.u. were challenged i.n. (Williamson et al., 1990) 1 month later with a lethal dose of wild-type WR (5 × 10⁶ p.f.u.) and the resulting weight loss was monitored daily. Data are expressed as the percentage ± SEM of the mean weight of the same group of animals on day 0. Significant differences between groups are shown, as determined using the Student’s t-test (*P < 0.05). Data shown are representative of at least two experiments. All panels share the same figure legend, which is depicted in (b).
and this was statistically significant at 3 days post-challenge, corresponding with the time of maximum weight loss (Fig. 1d). In contrast, no difference in protection was observed with the 10^3 p.f.u. per ear vaccination dose (Fig. 1e). Taken together these data indicated that vaccination of mice with vΔC6 provided better protection against subsequent VACV infection.

To understand the immunological basis of the enhanced protection provided by vΔC6, serological analysis was performed 1 month post-vaccination. The binding of serum antibodies to VACV-specific epitopes was assessed by ELISA, using plates that had been coated with a whole-cell lysate prepared from VACV-infected cells (Law et al., 2005; Pütz et al., 2006). Furthermore, the neutralization capacity of circulating antibodies was assessed by a plaque-reduction neutralization assay specific to the intracellular mature virion (IMV) form of VACV (Pütz et al., 2006). Whereas the end-point antibody titre was equivalent between the groups of vaccinated animals (Fig. 2a), the dilution of antibody that provided 50 % neutralization (ND50) of IMV was lower in the vΔC6-vaccinated mice, indicating perturbation of the humoral response by this

Fig. 2. Humoral responses 1 month post-vaccination. Antibody end-point titres against VACV proteins (a) were determined by ELISA (Law et al., 2005) from the serum of groups of five C57BL/6 mice that were vaccinated with 10^4 p.f.u., or mock-vaccinated with PBS in both ear pinnae. End-point titres were defined as the reciprocal serum dilution giving twice the optical density obtained from BSA. A control serum from a mouse immunized with VACV was used to normalize end-point titres between ELISA plates (Pütz et al., 2006). The neutralization capacity of antibodies in the serum of the animals described above was assessed by plaque-reduction neutralization (b) against VACV strain WR intracellular mature virus that had been purified by sucrose-density-gradient centrifugation (Pütz et al., 2006). ND50 values were defined as the reciprocal of the dilution of serum giving a 50 % reduction in plaque number. For the VACV-vaccinated animals, data from three separate experiments were pooled. The median value for each population is represented by a horizontal black bar. Significant differences between groups are shown, as determined using the Mann–Whitney test.

Fig. 3. CD8^+ T-cell responses 1 month post-vaccination. The cytolytic activity of T-cells derived from the spleens of groups of five C57BL/6 mice that had been vaccinated with 3×10^3 p.f.u. of the indicated viruses, or mock vaccinated with PBS in both ear pinnae, was determined by ^51Cr release assay (a) (Clark et al., 2006). Cytolytic activity of splenic T-cells was assayed against VACV strain WR-infected EL-4 target cells and is presented as the mean percentage ± SEM. IFN-γ release by splenic T-cells of mice vaccinated as described above was assessed by ELISPOT assay (b) (Clark et al., 2006). T-cells were stimulated to release IFN-γ ex vivo by incubation with WR-infected EL-4 target cells or the C57BL/6- and CD8^+/-specific B820–27 peptide (+ve) (Tscharke et al., 2005). As a control, T-cells were also stimulated with mock-infected EL-4 cells or the BALB/c-specific E3140–148 peptide (−ve) (Tscharke et al., 2006). Data are presented as the mean number of spots per million splenocytes ± SEM. Significant differences between data obtained for vΔC6 from both vC6WR and vC6Rev are indicated, as analysed by the Student’s t-test (⁎P<0.05). Data are representative of at least two experiments.
virus (Fig. 2b). Interestingly, a lower antibody neutralization capacity has also been observed with a recombinant WR virus lacking Bcl-2 family member K7 (unpublished data), an intracellular inhibitor of both NF-κB and IRF3 activation (Schröder et al., 2008). Taken together these data indicated that the enhanced protection observed with vAC6 was unlikely to be attributable to altered antibody responses.

To test whether vAC6 was a better vaccine due to enhanced T-cell responses, a chromium release cytotoxicity assay was performed (Clark et al., 2006). Spleens were harvested from mice 1 month post-vaccination, and splenocytes were prepared and incubated with VACV-infected EL-4 target cells that had been loaded with 51Cr. The percentage specific chromium release was higher using cells from vAC6-vaccinated animals at effector-to-target ratios of 25:1, 50:1 and 100:1, and this was statistically significant at the latter ratio (Fig. 3a). The total number of CD4+ and CD8+ T-cells in the spleen of vaccinated animals at this time point was equivalent between the various groups of mice (data not shown). To assess whether the enhanced cytotoxic activity of T-cells correlated with enhanced release of IFN-γ, an enzyme-linked immunosorbent spot (ELISPOT) assay was performed on suspensions of splenocytes isolated at 1 month post-vaccination (Clark et al., 2006). IFN-γ release by T-cells in response to VACV-infected EL-4 cells, or the CD8+ and C57BL/6-specific VACV peptide B8.1–15 (Tscharke et al., 2005) was not different between the groups of vaccinated animals (Fig. 3b). Mock-infected EL-4 cells and a CD8+ VACV peptide specific for BALB/c mice, E3140–148 (Tscharke et al., 2006), were used as negative controls and IFN-γ release in response to these stimuli was minimal, as expected. Furthermore, no difference in the number of IFN-γ or tumour necrosis factor alpha (TNF-α)-secreting CD8+ cells from the spleens of vaccinated animals at 1 month post-vaccination was observed by intracellular cytokine staining (data not shown). Together, these data indicated that the VACV-specific cytotoxic T-cell activity 1 month post-vaccination was higher in the spleens of vAC6-vaccinated mice, but a correlation with increased IFN-γ and/or TNF-α release at the dose tested was not found.

In this study, the vaccine efficacy of vAC6 was compared to control viruses expressing C6 at three different vaccination doses. Interestingly, where vAC6 induced a smaller lesion than control viruses during the primary inoculation (i.e. 104 and 3 × 103 p.f.u.), there was also lower post-challenge weight loss (Fig. 1). On the other hand at an inoculation dose of 103 p.f.u., where no difference in lesion size was observed between the three viruses, a difference in weight loss upon challenge was also not observed. Even VACV mutants that have increased virulence in the i.d. model can sometimes induce enhanced protection upon challenge. For instance, a VACV lacking the chemokine-binding protein A41 induced a larger lesion than WT VACV and yet provided enhanced protection (Clark et al., 2006). Equally the removal of an immune modulator does not always lead to enhanced protection upon challenge, as exemplified by a recombinant VACV lacking protein C16 (Fahy et al., 2008). Understanding why the removal of certain immune modulators leads to enhanced immunogenicity and why others do not warrants further investigation. Previously, it was demonstrated that a candidate HIV vaccine vector based on a recombinant MVA lacking C6 (MVA-B ΔC6) induced enhanced T-cell and antibody responses to the HIV antigens encoded by MVA-B compared with WT MVA-B (García-Arriaza et al., 2011). However, whether this translates into enhanced protection against HIV infection remains to be determined (García-Arriaza et al., 2011). Here, we show that removing C6 from VACV WR enhanced VACV-specific cytotoxic T-cell responses and resulted in a more efficacious vaccine that provided better protection against challenge.

In summary, data presented demonstrate that VACV strain WR lacking the expression of C6 was more immunogenic than control viruses, providing better protection against challenge with a lethal dose of VACV, despite being attenuated. This enhanced immunogenicity was not attributed to humoral responses, but instead correlated with enhanced VACV-specific cytotoxic T-cell activity 1 month post-vaccination. These data demonstrate that the removal of an intracellular innate immune modulatory protein can impact on the ensuing adaptive and memory immune responses. Fully understanding the mechanisms of how modulation of the innate response affects memory immunity is an important and interesting challenge for the future and will impact vaccine design.

Acknowledgements

This work was supported by grants from the UK Medical Research Council and the Wellcome Trust. G. L. S is a Wellcome Trust Principal Research Fellow. This work was carried out in accordance with regulations of the Animals (Scientific Procedures) Act 1986. All procedures were approved by the UK Home Office and carried out under the Home Office project licence PPL 70/7116.

References

Assarsson, E., Greenbaum, J. A., Sundström, M., Schaffer, L., Hammond, J. A., Pasquetto, V., Oseroff, C., Hendrickson, R. C., Lefkowitz, E. J. & other authors (2008). Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A 105, 2140–2145.

Bennink, J. R., Yewdell, J. W., Smith, G. L., Moller, C. & Moss, B. (1984). Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 311, 578–579.

Blanchard, T. J., Alcamì, A., Andrea, P. & Smith, G. L. (1998). Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79, 1159–1167.

Clark, R. H., Kenyon, J. C., Bartlett, N. W., Tscharke, D. C. & Smith, G. L. (2006). Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol 87, 29–38.

Cottingham, M. G., Andersen, R. F., Spencer, A. J., Saurya, S., Furze, J., Hill, A. V. & Gilbert, S. C. (2008). Recombination-mediated genetic
Vaccinia virus lacking C6 is a more potent vaccine

eering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). *PLoS ONE* 3, e1638.

Delaloye, J., Roger, T., Steiner-Tardivel, O. G., Le Roy, D., Knaup Reymond, M., Akira, S., Petrelli, V., Gomez, C. E., Perdigueru, B. & other authors (2009). Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. *PLoS Pathog* 5, e1000480.

Fahy, A. S., Clark, R. H., Glyde, E. F. & Smith, G. L. (2008). Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence. *J Gen Virol* 89, 2377–2387.

Falivene, J., Del Médico Zajac, M. P., Pascutti, M. F., Rodriguez, A. M., Maeto, C., Perdigueru, B., Gómez, C. E., Esteban, M., Calamante, G. & Gherardi, M. M. (2012). Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. *PLoS ONE* 7, e32220.

Fenner, F., Anderson, D. A., Arita, I., Jeze, Z. & Ladnyi, I. D. (1988). *Smallpox and its Eradication*. Geneva: World Health Organisation.

Fujita, F., Taniguchi, Y., Kato, T., Narita, Y., Furuya, A., Ogawa, T., Sakurai, J., Itoh, M. & other authors (2003). Identification of NAP1, a regulatory subunit of IskB kinase-related kinases that potentiates NF-κB signaling. *Mol Cell Biol* 23, 7780–7793.

García-Arriaza, J., Nájera, J. L., Gómez, C. E., Tewabe, N., Sorzano, C. O., Calandra, M., Roger, T. & Esteban, M. (2011). A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. *PLoS ONE* 6, e24244.

Gómez, C. E., Nájera, J. L., Krupa, M. & Esteban, M. (2008). The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. *Curr Gene Ther* 8, 97–120.

Gómez, C. E., Perdigueru, B., Nájera, J. L., Sorzano, C. O., Jiménez, V., González-Sanz, R. & Esteban, M. (2012). Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. *J Virol* 86, 5026–5038.

González, J. M. & Esteban, M. (2010). A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. *Virol J* 7, 59.

Graham, S. C., Bahar, M. W., Cooray, S., Chen, R. A., Whalen, D. M., Abrescia, N. G., Alderton, D., Owens, R. J., Stuart, D. I. & other authors (2008). Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-κB rather than apoptosis. *PLoS Pathog* 4, e1000128.

Gubser, C., Hué, S., Kellam, P. & Smith, G. L. (2004). Poxvirus genomes: a phylogenetic analysis. *J Gen Virol* 85, 105–117.

Lane, J. M., Ruben, F. L., Neff, J. M. & Millar, J. D. (1969). Complications of smallpox vaccination, 1968. *N Engl J Med* 281, 1201–1208.

Law, M., Pütz, M. M. & Smith, G. L. (2005). An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonitis model. *J Gen Virol* 86, 991–1000.

Lefkowitz, E. J., Wang, C. & Upton, C. (2006). Poxviruses: past, present and future. *Virus Res* 117, 105–118.

Mackett, M., Smith, G. L. & Moss, B. (1982). Vaccinia virus: a selectable eukaryotic cloning and expression vector. *Proc Natl Acad Sci U S A* 79, 7415–7419.

Meyer, H., Sutter, G. & Mayr, A. (1991). Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. *J Gen Virol* 72, 1031–1038.

Moore, J. B. & Smith, G. L. (1992). Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor. *EMBO J* 11, 1973–1980.

Moss, B. (2007). *Poxviridae: the viruses and their replication*. In *Fields Virology*, 5th edn, pp. 2905–2946. Edited by D. M. Knipe. Philadelphia: Lippincott Williams & Wilkins.

Moss, B. (2011). Smallpox vaccines: targets of protective immunity. *Immunal Rev* 239, 8–26.

Panicali, D. & Paoletti, E. (1982). Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. *Proc Natl Acad Sci U S A* 79, 4927–4931.

Panicali, D., Davis, S. W., Weinberg, R. L. & Paoletti, E. (1983). Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. *Proc Natl Acad Sci U S A* 80, 5364–5368.

Pomerantz, J. L. & Baltimore, D. (1999). NF-κB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. *EMBO J* 18, 6694–6704.

Pütz, M. M., Midgley, J. M., Law, M. & Smith, G. L. (2006). Quantification of antibody responses against multiple antigens of the two infectious forms of vaccinia virus provides a benchmark for smallpox vaccination. *Nat Med* 12, 1310–1315.

Reading, P. C., Moore, J. B. & Smith, G. L. (2003a). Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. *J Exp Med* 197, 1269–1278.

Reading, P. C., Symons, J. A. & Smith, G. L. (2003b). A soluble chemokine-binding protein from vaccinia virus reduces virus virulence and the inflammatory response to infection. *J Immunol* 170, 1435–1442.

Rehm, K. E. & Roper, L. R. (2011). Deletion of the A35 gene from modified vaccinia virus Ankara increases immunogenicity and isotype switching. *Vaccine* 29, 3276–3283.

Rzychakov, G. & Randow, F. (2007). SINTBAD, a novel component of innate antiviral immunity, shares a TK1-binding domain with NAP1 and TANK. *EMBO J* 26, 3180–3190.

Schröder, M., Baran, M. & Bowie, A. G. (2008). Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKK-α-mediated IRF activation. *EMBO J* 27, 2147–2157.

Smith, G. L., Mackett, M. & Moss, B. (1983a). Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. *Nature* 302, 490–495.

Smith, G. L., Murphy, B. R. & Moss, B. (1983b). Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. *Proc Natl Acad Sci U S A* 80, 7155–7159.

Staib, C., Kising, S., Erfle, V. & Sutter, G. (2005). Inactivation of the viral interleukin 1β receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. *J Gen Virol* 86, 1997–2006.

Tschanke, D. C. & Smith, G. L. (1999). A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. *J Gen Virol* 80, 2751–2755.

Tschanke, D. C., Reading, P. C. & Smith, G. L. (2002). Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. *J Gen Virol* 83, 1977–1986.

Tschanke, D. C., Karupiah, G., Zhou, J., Palmore, T., Irvine, K. R., Haeryfar, S. M., Williams, S., Sidney, J., Sette, A. & other authors (2005). Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. *J Exp Med* 201, 95–104.

Tschanke, D. C., Woo, W. P., Sakala, I. G., Sidney, J., Sette, A., Moss, D. J., Bennink, J. R., Karupiah, G. & Yewdell, J. W. (2006). Poxvirus
CD8+ T-cell determinants and cross-reactivity in BALB/c mice. 
*J Virol* 80, 6318–6323.

Unterholzner, L., Sumner, R. P., Baran, M., Ren, H., Mansur, D. S., Bourke, N. M., Randow, F., Smith, G. L. & Bowie, A. G. (2011). Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. *PLoS Pathog* 7, e1002247.

Upton, C., Slack, S., Hunter, A. L., Ehlers, A. & Roper, R. L. (2003). Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome. *J Virol* 77, 7590–7600.

Williamson, J. D., Reith, R. W., Jeffrey, L. J., Arrand, J. R. & Mackett, M. (1990). Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. *J Gen Virol* 71, 2761–2767.